Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2163813. doi: 10.1080/21645515.2022.2163813. Epub 2023 Jan 27.
Limited data are available on the effectiveness of COVID-19 vaccines used in China in real-world outbreaks - especially against Omicron variants in vaccinated individuals. Two outbreaks of SARS-CoV-2 Omicron variants - the first involving the sub-lineage BA.2 and the second the BA.1 variant - occurred in Quzhou. Infected people and their close contacts were divided according to vaccination status: unvaccinated, partially vaccinated, fully vaccinated, and boosted. The Cox proportional-hazard regression model was used to estimate the evolving hazard for vaccinated individuals after their first immunization. 138 people had been infected with the SARS-CoV-2 Omicron BA.2 variant and 13 with the BA.1 variant. Of the 151 infections, 99.34% (150/151) were mild or asymptomatic and 90.07% (136/151) were vaccine breakthrough cases. The total vaccine effectiveness (VE) of partial, full, and booster vaccinations during the two outbreaks was 47.4% (95%CI: 0-93.1%), 28.9% (95%CI: 0-60.2%), and 27.5% (95%CI: 0-58.3%). The VE of booster vaccination against the Omicron BA.1 variant was higher than that for the BA.2 variant. The cumulative hazard began to increase 220 days after the first immunization. The transmissibility of the Omicron BA.2 variant as for BA.1 did not increase in vaccinated individuals; booster vaccination after a primary course substantially increased protection. Our study found that the SARS-CoV-2 Omicron variant caused less severe illness and that the VE of boosters against the Omicron variant was less than 30%. Timely administration of the booster dose was important, especially for individuals aged over 80 years old.
在中国的真实世界疫情中,关于已使用的 COVID-19 疫苗的有效性数据有限 - 特别是针对接种疫苗个体的奥密克戎变异株。在衢州发生了两起 SARS-CoV-2 奥密克戎变异株疫情 - 第一次涉及亚谱系 BA.2,第二次涉及 BA.1 变异株。感染者及其密切接触者根据接种状态进行了划分:未接种、部分接种、完全接种和加强接种。使用 Cox 比例风险回归模型来估计接种者在首次免疫后的危险率变化。有 138 人感染了 SARS-CoV-2 奥密克戎 BA.2 变异株,13 人感染了 BA.1 变异株。在 151 例感染中,99.34%(150/151)为轻症或无症状,90.07%(136/151)为疫苗突破性病例。在两次疫情中,部分、完全和加强接种的总疫苗效力(VE)分别为 47.4%(95%CI:0-93.1%)、28.9%(95%CI:0-60.2%)和 27.5%(95%CI:0-58.3%)。加强接种对奥密克戎 BA.1 变异株的 VE 高于 BA.2 变异株。首次免疫后 220 天,累积危险率开始增加。接种疫苗者中奥密克戎 BA.2 变异株的传染性与 BA.1 相同,初级疗程后的加强接种大大增加了保护。我们的研究发现,SARS-CoV-2 奥密克戎变异株引起的疾病较轻,而针对奥密克戎变异株的加强针 VE 低于 30%。及时接种加强针很重要,特别是对于 80 岁以上的个体。
Hum Vaccin Immunother. 2023-12-31
Hum Vaccin Immunother. 2023-12-31
Zhonghua Liu Xing Bing Xue Za Zhi. 2022-11-10
J Infect Dis. 2023-2-1
Hum Vaccin Immunother. 2022-11-30
Lancet Infect Dis. 2022-7